HOMA-beta in the UKPDS and ADOPT. Is the natural history of type 2 diabetes characterised by a progressive and inexorable loss of insulin secretory function? Maybe? Maybe not?
UK Prospective Diabetes Study Group (1995) UK prospective diabetes study 16: overview of 6 years of therapy of type II diabetes: a progressive disease. Diabetes44: 1249-58.
2.
Matthews, DR , Hosker, JP, Rudenski , AS, et al. (1985) Homeostasis Model Assessment (HOMA): insulin resistance and beta cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia28: 412-19.
3.
Kahn, SE, Haffner, SM, Heise, MA, et al. (2006) Glycemic durability of rosiglitazone, metformin, or glyburide mono-therapy. N Engl J Med355: 2427-43.
4.
Turner, RC, Cull, CA, Fright, V., Holman, RR for the UK Prospective Diabetes Study Group (1999) Glycemic control with diet, sulfonuylurea, metformin, or insulin in patients with type 2 diabetes: Progressive requirement of multiple therapies (UKPDS 49). JAMA281: 2005-12.
5.
Dupre, J. (1970) Regulation of the secretions of the pancreas. Ann Rev Med21: 299-316
6.
Peterson, DT , Reaven, GM (1971) Evidence that glucose load is an important determinant of plasma insulin response in normal subjects . Diabetes20: 729-33.
7.
Hollenbeck, C. , Reaven, GM (1987) Variations in insulin-stimulated glucose uptake in healthy individuals with normal glucose tolerance. J Clin Endocrinol Metab64: 1169-73.
8.
Jones, NO, Pei, D., Staris, P., et al. (1997) Alterations in the glucose-stimulated insulin secretory dose-response curve and in insulin clearance in nondiabetic insulin-resistant individuals. J Clin Endocrinol Metab82: 1834-38
9.
Byrne, MM, Sturis, J, Polonsky, (1995) Insulin secretion and clearance during low-dose graded glucose infusion. Am J Physiol268: E21-E27.
10.
Reaven, GM, Chen, Y-DI, Hollenbeck, CB, Sheu, WHH, Ostrega, D., Polonsky, KS (1993) Plasma insulin, C-peptide, and proinsulin concentrations in obese and nonobese individuals with varying degrees of glucose tolerance . J Clin Endocrinol Metab76: 44-8.
11.
Reaven, GM, Hollenbeck, C., Jeng, C-Y., Wu, M-S., Chen, Y-DI (1988) Measurement of plasma glucose, free fatty acid, lactate, and insulin for 24 h in patients with NIDDM. Diabetes37: 1020-24.
12.
Andrews, WJ , Vasquez, B., Nagulesparan , M., et al. (1984) Insulin therapy in obese, non-insulin dependent diabetes induces improvements in insulin action and secretin that are maintained for two weeks after insulin withdrawal. Diabetes33: 634-42.
13.
Liu, G. , Coulston, AM, Lardinois , CK, Hollenbeck, CB, Moore, J., Reaven, G. (1985) Moderate weight loss and sulfonylurea treatment of non-insulin dependent diabetes mellitus: Combined effects. Arch Int Med145: 665-69.
14.
Reaven, G. and the staff of the Palo Alto GRECC Study Unit. (1985) Beneficial effect of moderate weight loss in older patients with non-insulin dependent diabetes mellitus poorly controlled with insulin. J Am Geriatr Soc33: 93-5.
15.
Reaven, G., Dray, J. (1967) Effect of chlorpropamide on seru glucose and immunoreactive insulin concentrations in patients with maturity onset dabetes. Diabetes15: 487-92.
16.
Shenfield, GM, Logan, A., Shirling , D., Baird, J. (1977) Plasma insulin and glucose levels in maturity onset diabetes treated with chlorporpramide. Diabetologia13: 367-71.
17.
Reaven, GM (1995) Effect of metformin on various aspects of glucose, insulin and lipid metabolism in patients with non-insulin-dependent diabetes mellitus with varying degrees of hyperglycemia. Diab/Metab Rev11: S97-S108.
18.
Chu, JW , Abbasi, F., Lamendola , C., McLaughlin, T., Reaven, GM, Tsao, PS (2005) Effect of rosiglitazone treatment on circulating vascular and inflammatory markers in insulin-resistant subjects. Diabetes Vasc Dis Res2: 37-41.
